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Abstract
Inflammatory mechanisms, like microglial activation, could be involved in the pathogenesis of Alzheimer’s disease (AD). (R)-
[11C]PK11195 (1-(2-chlorophenyl)-N-methyl-N-1(1-methylpropyl)-3-isoquinolinecarboxamide), a positron emission tomography (PET)
igand, can be used to quantify microglial activation in vivo. The purpose of this study was to assess whether increased (R)-[11C]PK11195
binding is present in AD and mild cognitive impairment (MCI), currently also known as “prodromal AD.”
Methods: Nineteen patients with probable AD, 10 patients with prodromal AD (MCI), and 21 healthy control subjects were analyzed.
Parametric images of binding potential (BPND) of (R)-[11C]PK11195 scans were generated using receptor parametric mapping (RPM) with
supervised cluster analysis. Differences between subject groups were tested using mixed model analysis, and associations between BPND
and cognition were evaluated using Pearson correlation coefficients.
Results: Voxel-wise statistical parametric mapping (SPM) analysis showed small clusters of significantly increased (R)-[11C]PK11195
BPND in occipital lobe in AD dementia patients compared with healthy control subjects. Regions of interest (ROI)-based analyses showed
no differences, with large overlap between groups. There were no differences in (R)-[11C]PK11195 BPND between clinically stable
prodromal AD patients and those who progressed to dementia, and BPND did not correlate with cognitive function.
onclusion: Microglial activation is a subtle phenomenon occurring in AD.
2013 Elsevier Inc.
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Alzheimer’s disease (AD) is a neurodegenerative disor-
der, clinically characterized by progressive cognitive de-
cline and impaired execution of daily activities (McKhann
* Corresponding author at: Department of Neurology, Zuwe Hofpoort
ziekenhuis, PO Box 8000, 3440 JD Woerden, the Netherlands. Tel.: 31
348 427911.E-mail address: ASchuitemaker@zuwehofpoort.nl (A. Schuitemaker).
0197-4580 © 2013 Elsevier Inc.
http://dx.doi.org/10.1016/j.neurobiolaging.2012.04.021
Open access under the Elsevier OA license.et al., 1984). Patients with mild cognitive impairment (MCI)
have documented memory impairment but are still able to
perform daily activities in a normal manner. MCI is con-
sidered to be a transitional phase between normal aging and
AD (Petersen et al., 1999). Subjects with MCI have an
increased risk of developing clinical AD of about 12% per
year compared with 1%–2% in the general population (Pe-
tersen, 2004). Recently, new criteria for the diagnosis of AD
were proposed, which allows diagnosis related to neuro-
pathological changes in AD, based on the use of biomarkers
(
p
g
T
e
m
m
a
d
c
e
R
b
b
i
g
i
p
a
p
2
2
M
t
h
p
i
s
a
1
m
c
t
w
m
R
(
c
d
i
e
R
(
c
b
A
c
l
p
q
f
a
b
c
s
E
a
m
m
g
p
s
m
i
D
s
d
a
[
129A. Schuitemaker et al. / Neurobiology of Aging 34 (2013) 128–136of AD (Dubois et al., 2010). According to this new classi-
fication, patients with MCI are considered to have “prodro-
mal AD.”
AD is characterized histopathologically by intracellular
neurofibrillary tangles (NFT), extracellular deposits of am-
yloid in senile plaques, and diffuse loss of neurons (Braak
and Braak, 1991). Although not a pathological hallmark
specific to AD, activated microglia invariably are found in
AD, and they may be present years before symptoms be-
come apparent clinically (Petersen et al., 2006). Indeed,
activated microglia could be an important therapeutic target,
as microglial activation may be directly involved in the
neurodegenerative process associated with AD (Yoshiyama
et al., 2007).
Microglial activation can be quantified in vivo using
positron emission tomography (PET) and (R)-[11C]PK11195.
R)-[11C]PK11195 (1-(2-chlorophenyl)-N-methyl-N-1(1-methyl-
ropyl)-3-isoquinolinecarboxamide) is a highly specific li-
and for the peripheral benzodiazepine-binding site (PBR).
his site, also called the translocator protein (Papadopoulos
t al., 2006), is expressed by cells of the mononuclear
acrophage lineage and is markedly increased in activated
icroglia. Using (R)-[11C]PK11195 and PET, microglial
ctivation has already been demonstrated in several neuro-
egenerative diseases (Venneti et al., 2006). In AD, in-
reased (R)-[11C]PK11195 binding has been found in sev-
ral brain areas (Cagnin et al., 2001; Yokokura et al., 2011).
ecently, there have been two reports on (R)-[11C]PK11195
inding in MCI (Okello et al., 2009; Wiley et al., 2009). In
oth studies, (R)-[11C]PK11195 binding was assessed in
two cohorts of MCI patients, being 11C-labeled Pittsburgh
compound B ([11C]-PIB)-positive and -negative patients.
These studies found either increased (Okello et al., 2009) or
unchanged (Wiley et al., 2009) (R)-[11C]PK11195 binding
n MCI.
The purpose of the present study was to further investi-
ate the extent and distribution of (R)-[11C]PK11195 bind-
ng in larger cohorts of AD dementia and prodromal AD
atients. A second aim was to establish whether presence of
ctivated microglia in prodromal AD is associated with
rogression to AD dementia.
. Methods
.1. Subjects
Twenty patients with probable AD, 13 patients with
CI, and 21 healthy control subjects were included. Pa-
ients were recruited from the outpatient clinic of the Alz-
eimer center at the VU University Medical Center. All
atients underwent standardized clinical assessment, includ-
ng neurological and physical examinations, laboratory
creening tests (including cerebrospinal fluid measures of
myloid  (A), tau, and tau phosphorylated at threonine-
81) (Bouwman et al., 2010), electroencephalogram (EEG),
agnetic resonance imaging (MRI), and neuropsychologi-al examination. Final diagnosis was established at a mul-
idisciplinary consensus meeting. Diagnosis of probable AD
as based on National Institute of Neurological and Com-
unicative Disorders and Stroke-Alzheimer’s Disease and
elated Disorders Association (NINCDS-ADRDA) criteria
McKhann et al., 1984), and diagnosis of MCI on Petersen
riteria (Petersen et al., 1999). Subjects underwent a stan-
ard battery of examinations, including history taking, med-
cal and neurological examination, and neuropsychological
xamination, which consisted of the New York University
ecall Test (NYU), Rey’s Auditory Verbal Learning Test
RAVLT), Trail Making Test A and B, Fluency, Rey’s
omplex figure, Boston Naming Test, and forward and
ackward condition of the Digit Span.
According to recently proposed criteria for prodromal
D (Dubois et al., 2010), MCI and AD patients were ex-
luded from the analysis if there was no medial temporal
obe atrophy (MTA) or no abnormal cerebrospinal fluid
rofile (Bouwman et al., 2010) (one MCI patient). Conse-
uently, MCI will be reported as prodromal AD. For clinical
ollow-up, prodromal AD patients visited the memory clinic
nnually. One patient progressed to dementia with Lewy
odies and was excluded from the analyses.
Control subjects without cognitive complaints were re-
ruited by advertisement in local newspapers. All control
ubjects underwent the same diagnostic procedure (except
EG and lumbar puncture). Control subjects had to have
ge-corrected normal scores on neuropsychological assess-
ents and a normal MRI (including MTA scores) (Bouw-
an et al., 2010), which was evaluated by a neuroradiolo-
ist.
Exclusion criteria for all subjects were known major
sychiatric illness, previous head trauma with loss of con-
ciousness of more than 1-hour duration, any significant
etabolic disorder, and alcohol or substance abuse accord-
ng to the Diagnostic and Statistical Manual of Mental
isorders-IV (DSM-IV) criteria (American Psychiatric As-
ociation, 2000). Intake of benzodiazepines, antipsychotic
rugs, and non-steroidal anti-inflammatory drugs was not
llowed because of possible interaction with (R)-
11C]PK11195 binding. Written informed consent was ob-
tained from all participants and in case of patients with AD
also from a next of kin. The study protocol was approved by
the Medical Ethics Review Committee of the VU University
Medical Center.
2.2. MRI
All subjects had a structural MRI scan within 4 months
of the PET procedure. MRI scans were acquired using a
1.0-T scanner (Magnetom IMPACT, Siemens Medical So-
lutions, Erlangen, Germany) and included a 3D heavily
T1-weighted gradient echo sequence (magnetization pre-
pared rapid acquisition gradient echo). Voxel size of the
MRI images was 0.98  0.98  1.49 mm3. These scans
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and for delineation of regions of interest (ROI).
2.3. Production of (R)-[11C]PK11195
(R)-[11C]PK11195 was produced according to published
methods (Shah et al., 1994). Each (R)-[11C]PK11195 injec-
tion solution met the following pharmaceutical specifica-
tions: specific activity (SA)  18.5 GBq mol1; radio-
chemical purity  98%; 5  pH  8.
2.4. PET
PET scans were acquired using an ECAT EXACT HR
(Siemens/CTI, Knoxville, TN, USA) (Brix et al., 1997).
First, a 10-minute transmission scan was performed in 2D
acquisition mode using three retractable rotating line
sources. This scan was used to correct the subsequent emis-
sion scan for photon attenuation. Then, a 3D dynamic (R)-
[11C]PK11195 emission scan was performed consisting of
22 frames with progressive increase in frame duration (1 
30 background, 1  15, 1  5, 1  10, 2  15, 2  30, 3 
0, 4  150, 5  300, and 2  600 seconds; total acqui-
ition time 60.5 minutes). Detailed scanning procedures
ave been described previously (Mourik et al., 2010; Schu-
temaker et al., 2007a, 2012). Subject motion during scan-
ing was checked visually at regular intervals (by checking
he position of the head using laser beams) and corrected
mmediately, if necessary.
.5. Image reconstruction
All PET sinograms were corrected for dead time, tissue
ttenuation using the transmission scan, decay, scatter, and
andoms. Data were reconstructed using a filtered back
rojection (FBP) reconstruction algorithm (Ollinger and
essler, 1997), as well as a partial volume-corrected (PVC)
rdered subset expectation maximization (OSEM) recon-
truction algorithm that incorporates the scanner’s point
pread function in the system matrix during reconstruction.
his PVC-OSEM algorithm has been validated previously.
or PVC-OSEM, 4 iterations with 16 subsets and no loop or
ostfilter were used (Hudson and Larkin, 1994). Recon-
tructed images were filtered using a Hanning filter of 5 mm
ull width at half maximum (FWHM), both in transaxial and
xial directions. A zoom factor of 2 and a matrix size of
56  256  63 were used, resulting in a voxel size of 1.2
1.2  2.4 mm3 and a spatial resolution of approximately
.5-mm full width at half maximum in the center of the field
f view. Images were then transferred to workstations (Sun
icrosystems, Santa Clara, CA, USA) for further analysis.
ne AD and one prodromal AD patient were excluded
ecause of insufficient quality of the PET scans for regional
nalyses (movement artefacts).
.6. Data analysis
Parametric images of binding potential (BPND) of (R)-
[11C]PK11195 were generated using receptor parametric bmapping (RPM) (Gunn et al., 1997), a basis function im-
plementation of the simplified reference tissue model
(SRTM) (Lammertsma and Hume, 1996). RPM was found
to be the most suitable parametric method for analysis of
(R)-[11C]PK11195 data (Schuitemaker et al., 2007a). Super-
vised cluster analysis was used to extract the reference
tissue input curve directly from the dynamic (R)-
[11C]PK11195 data (Turkheimer et al., 2007). The primary
outcome measure was BPND (Innis et al., 2007; Lam-
mertsma and Hume, 1996).
2.7. Regions of interest definition
For each subject, PET and MRI scans were coregistered
using the software package MIRIT (Maes et al., 1997; West
et al., 1997). ROI were drawn manually on bilateral hip-
pocampus, amygdala, entorhinal cortex, and lateral and su-
perior temporal lobe using the software program DISPLAY,
developed at the McConnell Brain Imaging Centre (BIC) of
the Montreal Neurological Institute, McGill University (www.
bic.mni.mcgill.ca/ServicesSoftwareVisualization/Home
Page). ROIs were drawn manually by a trained researcher
(A.S.) on the individual MRI scans in a plane by plane
fashion according to anatomic structures. These 2D ROI can
be defined in transaxial, coronal, and sagittal planes, and
these orientations used for ROI definition could be changed
anytime throughout the manual delineation process, thereby
facilitating generations of 3D ROIs. In addition, template
ROIs were defined using probability map-based automatic
brain delineation (Svarer et al., 2005). ROIs in this template
include the frontal cortex (volume-weighted average of su-
perior frontal, orbital frontal, and medial inferior frontal
cortex), cingulate posterior cortex, thalamus, parietal cortex,
and occipital cortex. Regional values of BPND were ob-
ained by projecting the manual and template ROIs, defined
bove, onto the parametric BPND images.
2.8. Statistical analysis
Statistical analyses of ROI data were performed using
SPSS software (SPSS Institute, Chicago, IL, USA), version
15.0. Values are presented as mean  standard deviation
(SD). Differences in clinical characteristics, tracer doses,
and specific activity between different subject groups were
tested using analysis of covariance (ANCOVA) with post
hoc Bonferroni corrections and age as a covariate. A linear
mixed model was used to assess group differences in re-
gional binding. Mixed models use all data available from all
cortical regions, properly account for within-person corre-
lations over the different cortical regions, and appropriately
handle missing data. The model included diagnosis, region,
and interaction of diagnosis and region. Age was used as a
covariate, and BPND was the dependent variable. The threshold
for significance was set at p  0.05. Analyses were repeated
ith prodromal AD and AD combined as one patient group
nd compared with healthy control subjects. Associations
etween (R)-[11C]PK11195 binding and cognitive test re-
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adjusted for multiple comparisons.
2.9. Voxel-wise analysis
Voxel-wise analysis of parametric BPND images was
performed using statistical parametric mapping (SPM)
(SPM2; www.fil.ion.ucl.ac.uk/spm). The purpose of this
analysis was to assess whether there were clusters of voxels
with altered binding that could not be identified in the ROI
analysis, for example due to heterogeneity within and across
ROIs. As voxel-wise analysis is very sensitive to patient
movement, scans were checked visually for motion artefacts
prior to SPM analysis. Standard additional smoothing
within SPM using a 10-mm full width at half maximum
Gaussian filter was performed to reduce noise to acceptable
levels and to obtain sufficient overlap of structures between
subjects for SPM analysis. Differences between AD demen-
tia or prodromal AD patients (and subgroups of [non]con-
verters) and healthy control subjects were assessed in a
voxel-wise comparison, using two sample t tests. SPM anal-
yses were performed without proportional scaling. Propor-
tional scaling can be omitted because RPM plots are quan-
titatively accurate even at lower noise levels, as shown
previously (Schuitemaker et al., 2007b). SPM results were
thresholded at both p  0.01 and p  0.001. The false
iscovery rate method to correct for multiple comparisons
ithin SPM was used to provide corrected p-values (Geno-
ese et al., 2002).
. Results
.1. Demographic and clinical data
Baseline characteristics of participants, eligible for anal-
sis, are presented in Table 1. There were no differences in
ge or gender between AD patients, prodromal AD patients,
nd healthy control subjects. MTA score was lower in
ealthy control subjects compared with prodromal AD or
D dementia patients. AD dementia patients had lower
ini-Mental State Examination (MMSE) scores (Folstein et
l., 1975) than healthy control subjects and prodromal AD
atients, and scores in prodromal AD patients were lower
han those in healthy control subjects. AD dementia patients
nd prodromal AD patients had lower scores on the NYU
aragraph recall test, the RAVLT, and the backwards con-
ition of the digit span compared with control subjects. AD
ementia patients had higher scores on the trail making test
compared with control subjects and prodromal AD, and
n the trail making test B compared with control subjects.
even of the 10 prodromal AD patients progressed clini-
ally and fulfilled AD dementia criteria at follow-up. Three
atients remained clinically stable until they were lost to
ollow up (mean follow-up duration was 2.7  0.5 years;
ange, 2.3–3.3 years). Mean duration of follow-up for pa-
ients until converting to dementia was 2.6 years (SD 1.6;
ange, 1.1–5.8 years). Prodromal AD patients who con-erted to AD dementia had higher scores on the forward
ondition of the digit span than patients who did not convert
6.3 vs. 4.7; p  0.011). Otherwise, there were no differ-
nces in cognitive test results at baseline between converters
nd nonconverters (p  0.05).
.2. (R)-[11C]PK11195 administration
There were no differences in injected tracer dose or
specific activity between subject groups. Mean tracer dose
was 350  102, 295  159, and 303  87 MBq (F(2,45) 
1.14, p  0.33), and mean specific activity was 79  36,
4  41, and 92  35 Gbq·mol1 (F(2,47)  0.62, p 
.54) in AD dementia patients, prodromal AD patients, and
ealthy control subjects, respectively. Estimated receptor
ccupancy associated with these high SA tracer doses was
1%.
.3. ROI analysis
In Table 2, RPM-derived BPND values of (R)-[11C]PK11195
re shown for different brain regions in AD dementia patients,
rodromal AD patients, and healthy control subjects, using the
tandard FBP reconstruction algorithm. Linear mixed models
howed no significant main effect of diagnostic group (p 
.53). There was an effect of brain region (p  0.001). No
nteraction was found (p  0.11), indicating that regional
ifferences were similar across diagnostic groups. This is also
llustrated in Fig. 1, showing BP values in the different subject
roups. In general, BPND was highest in frontal lobe, posterior
ingulate cortex, thalamus, parietal, and occipital lobes. Re-
ults were similar (main effect of brain region [p 0.001], but
o main effect of diagnostic group [p  0.93] and no interac-
tion [p 0.13]) when images with higher spatial resolution, as
obtained with the PVC-OSEM reconstruction algorithm, were
Table 1
Subject characteristics
Controls Prodromal AD AD
21 10 19
ge (years) 68  8 72  6 69  8
Sex M : F 13 : 8 7 : 3 11 : 8
MTA score 0.3  0.4 1.3  0.6 1.5  0.9
MMSEa,b,c 29  1 26  1 23  3
NYU test scorea,b 9.2  4.2 3.9  1.7 1.3  1.9
RAVLTa,b 8.6  3.2 2.1  2.2 0.4  0.7
Trail Ab,c 43  12 46  14 71  22
Trail Bb 89  34 139  68 190  87
Digit forward 6.4  0.9 5.8  1.0 6.1  1.0
Digit backwarda,b 5.7  1.1 3.7  0.5 4.5  1.2
Data are represented as mean  SD.
Key: AD, Alzheimer’s disease; MTA score, mean medial temporal lobe
atrophy; MMSE, Mini-Mental State Examination; NYU, New York Uni-
versity paragraph recall test; RAVLT, Rey’s Auditory Verbal Learning
Test; Trail A and B, trail making test A and B; Digit forward and back-
ward, forward and backward condition of the digit span.
a p  0.05 for controls vs. prodromal AD.
b p  0.05 for controls vs. AD.
c p  0.05 for prodromal AD vs. AD.used.
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132 A. Schuitemaker et al. / Neurobiology of Aging 34 (2013) 128–136When the analyses were repeated, with prodromal AD
and AD dementia combined as one patient group, compa-
rable results were obtained.
3.4. Voxel-wise analysis
Voxel-wise analysis of BPND images showed increased
R)-[11C]PK11195 binding in AD dementia patients com-
pared with healthy control subjects in bilateral occipital
cortex (p  0.01) (Fig. 2). At a higher statistical threshold
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
BPND 
Cingulate  
posterior 
Lateral  
temporal 
Superior 
temporal 
AmygdFrontal 
Fig. 1. (R)-[11C]PK11195 BP in healthy control subjects, prodromal Al
Table 2
Regional values of (R)-[11C]PK11195 BPND
ROIs Controls Prodromal AD AD
Frontal 0.182  0.101 0.202 0.128 0.231 0.127
ingulate
posterior
0.370  0.133 0.387 0.142 0.338 0.172
ateral temporal 0.054  0.094 0.067 0.111 0.079 0.108
uperior
temporal
0.132  0.141 0.136 0.167 0.177 0.092
mygdala 0.103  0.171 0.167  0.193 0.054  0.167
ippocampus 0.049  0.112 0.032  0.207 0.014  0.120
ntorhinal 0.156  0.145 0.080  0.240 0.047  0.176
Thalamus 0.234  0.090 0.279 0.168 0.311 0.182
Parietal 0.202  0.124 0.234 0.156 0.199 0.134
Occipital 0.439  0.108 0.462 0.054 0.427 0.144
Data are represented as mean  SD.
Key: ROIs, regions of interest; AD, Alzheimer’s disease.ND
with prodromal AD who remained clinically stable, □  patients with prodroma(p  0.001), no increased signal was found. No differences
in (R)-[11C]PK11195 binding between prodromal AD pa-
tients (and subgroups) and healthy control subjects or AD
dementia patients were found. When the analyses were
repeated with prodromal AD patients and AD dementia
patients as one group and compared with healthy control
subjects, no differences were found.
3.5. (R)-[11C]PK11195 binding potential and cognition
There were no correlations with cognitive tests at base-
line and (R)-[11C]PK11195 BPND in any region. There was
no difference in BPND between prodromal AD patients who
emained clinically stable and those who progressed clini-
ally to dementia.
. Discussion
In this study, only small clusters of increased (R)-
11C]PK11195 binding were found in bilateral occipital lobe
in AD dementia patients using a voxel-based analysis. ROI-
based analyses showed no differences between diagnostic
groups, with large overlap between subject groups. This
suggests that microglial activation in AD is a subtle phe-
nomenon, which is present in AD dementia.
ROI
Hippocampus Entorhinal 
cortex 
Thalamus Parietal Occipital 
r’s disease (AD), and AD dementia patients.   controls,   patientala 
zheime
l AD who progressed to dementia, and ‘  AD dementia patients.
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133A. Schuitemaker et al. / Neurobiology of Aging 34 (2013) 128–136Quantification of (R)-[11C]PK11195-specific binding (BPND)
as performed using RPM (Schuitemaker et al., 2007a) and
modified supervised cluster analysis (Boellaard et al.,
008; Turkheimer et al., 2007; Yaqub et al., 2009) to extract
he reference tissue input curve. Given the relatively low
pecific signal in AD and especially prodromal AD, it is
ssential to use optimal methodology. For quantification,
se of a pure enantiomer, in this case (R)-[11C]PK11195, is
andatory (Shah et al., 1994). In addition, it has been
hown that in pathological conditions like AD, with reduced
ow rates or variations in blood volume, a basis function
ethod is preferred above other simplified methods, such as
tandardized uptake values (Hoekstra et al., 2000) or (ref-
rence) Logan plot analysis (Logan et al., 1990, 1996), for
nalyzing (R)-[11C]PK11195 data because it produces less
ias and is more precise (Schuitemaker et al., 2007a). As
uch, RPM with an optimized supervised cluster analysis to
xtract the reference tissue curve was used in this study.
The present findings are largely in agreement with previous
R)-[11C]PK11195 studies in AD, in which cluster (Cagnin et
l., 2001) or supervised cluster analysis methods (Edison et al.,
008) were used to derive the reference region and in which
Fig. 2. Regions with increased (R)-[11C]PK11195 BPND in Alzheimer’s di
at p  0.01. Extent threshold  10 voxels. The colour bar indicates T val
method within SPM. For interpretation of the references to color in this filso subtle increased (R)-[11C]PK11195 binding was demon-trated. To date, two (R)-[11C]PK11195 studies in MCI pa-
ients have been reported (Okello et al., 2009; Wiley et al.,
009). In both studies, (R)-[11C]PK11195 binding was exam-
ned in [11C]PIB-positive and -negative patients, where
[11C]PIB was used as a biomarker of disease severity. Wiley et
l. (2009) reported (R)-[11C]PK11195 binding in cerebellum,
mesial temporal cortex, sensorimotor cortex, frontal cortex,
parietal cortex, and posterior cingulate cortex but did not dem-
onstrate significant differences between diagnostic groups,
comparable with the present results. Okello et al. (2009) did
demonstrate increased (R)-[11C]PK11195 binding in the fron-
tal cortex in a small group of [11C]-PIB positive patients,
although no correlations between amyloid depositions, as mea-
sured with [11C]PIB, and (R)-[11C]PK11195 binding in frontal
cortex were found.
In the present study, only patients with the most common
subtype of MCI, amnestic MCI, currently defined as pro-
dromal AD (Dubois et al., 2010; Petersen et al., 1999), were
included. Neuropathological data indicate that many amnes-
tic MCI patients have already high numbers of plaques and
tangles (Morris et al., 2001; Petersen et al., 2006; Price and
Morris, 1999), especially in the medial temporal lobe (Pe-
ementia compared with healthy control subjects. Images were thresholded
ta were corrected for multiple comparisons using the false discovery rate
gend, the reader is referred to the Web version of this article.sease d
ues. Datersen et al., 2006; Price and Morris, 1999), as has been
q
b
d
c
p
A
i
s
t
l
b
r
c
s
b
p
e
t
n
(
e
c
c
r
e
a
e
r
s
d
t
e
m
“
i
e
m
p
m
m
i
s
2
d
d
t
c
b
(
t
n
m
g
a
v
i
e
c
b
s
p
t
i
D
134 A. Schuitemaker et al. / Neurobiology of Aging 34 (2013) 128–136acknowledged in the new proposed criteria for AD, in which
patients with biomarker-positive amnestic MCI are consid-
ered to have a predementia stage of AD (prodromal AD)
(Dubois et al., 2010). This is in agreement with postmortem
studies demonstrating that activation of microglia precedes
neurodegenerative changes in the neocortex (Rozemuller et
al., 1989; Veerhuis et al., 2003). Indeed, a gradual increase
of microglial activation with increasing Braak scores of
neurofibrillary changes and with Congo red-positive depos-
its has been reported (Arends et al., 2000; Hoozemans et al.,
2005). As clinicopathological and animal studies have dem-
onstrated that microglia are attracted to the site of amyloid
plaque formation (Arends et al., 2000; Meyer-Luehmann et
al., 2008), one could expect increased (R)-[11C]PK11195
binding in regions with reported A deposition. Conse-
uently, one might expect increased (R)-[11C]PK11195
inding in prodromal AD patients, who progress to AD
ementia, but also even earlier in preclinical AD. In this
ontext, regional increases in (R)-[11C]PK11195 binding in
rodromal AD might reflect early changes, associated with
 deposition, occurring before structural changes can be
seen. However, no differences in (R)-[11C]PK11195 bind-
ng were found between prodromal AD patients who stayed
table and those who progressed to dementia.
Moreover, although some trends were observed, none of
he observed correlations between cognitive scores at base-
ine and (R)-[11C]PK11195 BPND in any of the brain regions
in prodromal AD or AD dementia patients were significant
after correction for multiple statistical comparisons. Previ-
ously, Yokokura et al. (2011) examined (R)-[11C]PK11195
inding as well as [11C]-PIB and glucose metabolism in a
elatively small group of AD patients and demonstrated a
orrelation between (R)-[11C]PK11195 binding and MMSE
scores in AD. Okello et al. (2009) also explored correlations
between (R)-[11C]PK11195 binding and cognition in a
mall group of MCI patients and reported no correlations
etween (R)-[11C]PK11195 binding and MMSE in PIB-
ositive MCI patients, which is in agreement with the pres-
nt results. Because the sample size was relatively small and
he follow-up period relatively short, a larger study is
eeded to confirm these findings. Furthermore, to assess
R)-[11C]PK11195 binding in the earliest stages of AD, it
would also be interesting to study asymptomatic-at-risk or
presymptomatic AD subjects (Dubois et al., 2010).
Remarkably, ROI-based analyses showed relatively low
regional binding in the medial temporal lobe regions (Fig.
1). Relatively low BPND might be caused by partial volume
ffects, especially in relatively small regions surrounded by
erebrospinal fluid, such as hippocampus and entorhinal
ortex, or by a relatively higher binding in the reference
egion than that in the target region. To limit partial volume
ffects, a novel PVC-OSEM reconstruction algorithm was
lso applied, but this did not affect results. An alternative
xplanation could be that within an ROI, a relatively smaller
egion shows increased (R)-[11C]PK11195 binding. As auch, averaging all voxels within a predefined ROI may
ilute a potential signal in part of that ROI and could
herefore lead to false-negative findings. This might also
xplain the differences between voxel-based and ROI-based
ethods, as voxel-based methods do not suffer from this
dilution” effect.
The present results, describing only small areas with
ncreased (R)-[11C]PK11195 binding, suggest that microglia
activation in AD is a subtle phenomenon. An important
question is whether microglial activation plays a harmful or
beneficial role in the development of AD. The function of
microglia in the brain is twofold. In normal brain tissue,
they survey the brain environment and when structural or
functional integrity of the brain is threatened they transform
to activated states. When activated, microglia can have both
neuroprotective and neurotoxic roles (Akiyama et al.,
2000). As such, it is possible that activated microglia may
induce neuronal damage. In AD, microglial activation oc-
curs around neuritic plaques, where it may be involved in
the degradation and phagocytosis of A deposits (Akiyama
t al., 2000). This could constitute a beneficial effect of
icroglia activation. Activated microglia, however, are also
resent in areas with low amyloid load, indicating that other
echanisms than plaque formation appear to contribute to
icroglial activation (DiPatre and Gelman, 1997). Indeed,
n an animal model of AD, microglial activation and loss of
ynapses preceded tangle formation (Yoshiyama et al.,
007), suggesting that microglial activation and neuronal
amage are closely connected. Although preclinical studies
o not provide conclusive evidence for either a neuropro-
ective or neurotoxic role of activated microglia in AD,
onverging data indicate that “inflammatory processes may
e a driving force of the pathology associated with AD”
Wyss-Coray, 2006). As such, neuroprotective strategies
argeted at reducing microglial activity may be beneficial
ot only in AD dementia, but also in prodromal AD. If
icroglial activation is a causative factor for neuronal de-
eneration, it could be an important target for treatment of
ge-related cognitive problems. Imaging of microglial acti-
ation can contribute to better understanding of the role of
nflammation in AD. It might also be useful to monitor the
ffect of future preventive and therapeutic treatments in
linical trials.
In conclusion, small clusters of increased (R)-[11C]PK11195
inding were found in AD patients but not in prodromal AD
ubjects, indicating that microglial activation is a subtle
henomenon present in AD. Imaging of microglial activa-
ion may contribute to better understanding of the role of
nflammation in AD.
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